Gilder Gagnon Howe & Co. LLC lessened its stake in Repligen Co. (NASDAQ:RGEN) by 3.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 494,952 shares of the biotechnology company’s stock after selling 19,314 shares during the period. Gilder Gagnon Howe & Co. LLC’s holdings in Repligen were worth $61,181,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC increased its stake in Repligen by 48.1% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 200 shares of the biotechnology company’s stock worth $25,000 after buying an additional 65 shares during the period. Harbor Investment Advisory LLC bought a new position in Repligen during the 1st quarter worth about $28,000. Capital Advisory Group Advisory Services LLC bought a new position in Repligen during the 1st quarter worth about $29,000. CSat Investment Advisory L.P. bought a new position in Repligen during the 2nd quarter worth about $37,000. Finally, First Horizon Advisors Inc. grew its holdings in Repligen by 87.9% during the 2nd quarter. First Horizon Advisors Inc. now owns 419 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 196 shares in the last quarter. 97.87% of the stock is currently owned by institutional investors.
In other Repligen news, VP Ralf Kuriyel sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $153.79, for a total transaction of $768,950.00. Following the completion of the transaction, the vice president now directly owns 31,089 shares of the company’s stock, valued at approximately $4,781,177.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Thomas F. Ryan, Jr. sold 3,095 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $151.90, for a total transaction of $470,130.50. Following the transaction, the director now directly owns 4,559 shares of the company’s stock, valued at $692,512.10. The disclosure for this sale can be found here. Insiders have sold a total of 26,800 shares of company stock valued at $3,393,897 over the last three months. 1.70% of the stock is currently owned by insiders.
RGEN stock traded down $2.57 during trading on Friday, reaching $145.40. The company had a trading volume of 484,988 shares, compared to its average volume of 385,847. The firm has a 50-day simple moving average of $145.89 and a 200-day simple moving average of $120.09. The company has a market cap of $7.63 billion, a price-to-earnings ratio of 250.69, a price-to-earnings-growth ratio of 4.14 and a beta of 1.12. The company has a debt-to-equity ratio of 0.22, a quick ratio of 13.90 and a current ratio of 15.48. Repligen Co. has a twelve month low of $72.32 and a twelve month high of $159.97.
Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, July 30th. The biotechnology company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.14. The company had revenue of $87.46 million during the quarter, compared to analysts’ expectations of $78.11 million. Repligen had a net margin of 10.23% and a return on equity of 5.93%. Sell-side analysts expect that Repligen Co. will post 1.25 earnings per share for the current year.
Several research analysts have issued reports on RGEN shares. Stifel Nicolaus increased their target price on shares of Repligen from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Wednesday, May 27th. BidaskClub cut shares of Repligen from a “buy” rating to a “hold” rating in a report on Monday, August 17th. Finally, HC Wainwright raised their price target on shares of Repligen from $151.00 to $168.00 and gave the company a “buy” rating in a report on Monday, August 24th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $139.50.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Read More: Beige Book
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.